cxcr4
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2">CXCR4 (C-X-C Chemokine Receptor Type 4)</th></tr>
<tr><td>Gene</td><td>[CXCR4](/genes/cxcr4)</td></tr>
<tr><td>UniProt ID</td><td>[P61073](https://www.uniprot.org/uniprot/P61073)</td></tr>
<tr><td>PDB</td><td>3ODU, 3OE0, 6OIJ</td></tr>
<tr><td>Molecular Weight</td><td>39.8 kDa</td></tr>
<tr><td>Localization</td><td>Plasma membrane, endosomes</td></tr>
<tr><td>Family</td><td>G protein-coupled receptor (GPCR) family, chemokine receptors</td></tr>
<tr><td>Disease</td><td>HIV, Cancer, Neuroinflammation, ALS</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">186 edges</a></td>
</tr>
</table>
</div>
Overview
C-X-C chemokine receptor type 4 (CXCR4) is a G protein-coupled receptor that binds the chemokine CXCL12 (SDF-1). CXCR4 plays critical roles in neurodevelopment, neuroinflammation, and neurodegeneration. It is the primary coreceptor for HIV entry into cells and has emerged as a therapeutic target in multiple neurological diseases.
Structure
CXCR4 has the characteristic GPCR architecture:
- Seven transmembrane helices (TM1-7): Form the ligand-binding pocket
- N-terminal domain: Contains sulfated tyrosine residues critical for CXCL12 binding
- C-terminal tail: Contains phosphorylation sites for β-arrestin recruitment and desensitization
- Extracellular loops (ECL1-3): Contribute to ligand specificity
- Intracellular loops (ICL1-3): Mediate G protein coupling (primarily Gi/o)
Crystal structures show CXCR4 can form homodimers and heterodimers with other chemokine receptors[@wu2010].
Normal Function
CXCR4 has diverse physiological roles:
Neural Development: Guides neuronal migration and axon pathfinding via CXCL12 gradients[@li2013]
Neuroprotection: Activates survival pathways (PI3K/AKT, MAPK/ERK) in [neurons](/entities/neurons)
Stem Cell Homing: Retains neural progenitor cells in niches
Immune Cell Trafficking: Directs lymphocyte and microglial migration
Angiogenesis: Promotes blood vessel formation in CNSCXCR4 signaling activates multiple pathways:
- Gi/o → ↓cAMP, ↑PI3K/AKT → Cell survival
- Gi/o → RAS/MAPK → Proliferation, migration
- β-arrestin → ERK1/2 → Gene expression
CXCL12 (SDF-1) Ligand
CXCL12 (C-X-C motif chemokine 12), also known as stromal cell-derived factor-1 (SDF-1), is the sole endogenous ligand for CXCR4. This chemokine is expressed by various cell types in the central nervous system, including astrocytes, microglia, neurons, and endothelial cells [22]. The CXCL12/CXCR4 axis represents a critical signaling system that orchestrates cell migration, survival, and function throughout the nervous system [23].
The interaction between CXCL12 and CXCR4 triggers conformational changes in the receptor that promote G protein coupling and downstream signaling cascades. CXCL12 binding induces receptor dimerization, which is thought to enhance signal transduction efficiency. The chemokine gradient created by differential CXCL12 expression provides directional cues for migrating cells during development and repair.
Role in Neurodegeneration
CXCR4 has emerged as a significant contributor to multiple neurodegenerative diseases through its roles in neuroinflammation, neuronal survival, and glial cell function. The dysregulation of CXCR4 signaling has been documented in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and multiple sclerosis [24].
Amyotrophic Lateral Sclerosis (ALS)
CXCR4 is prominently implicated in ALS pathogenesis through multiple mechanisms [25]:
Motor Neuron Toxicity: CXCL12-CXCR4 signaling induces apoptosis in vulnerable motor neurons through activation of caspase-3 and mitochondrial dysfunction. The elevated CXCL12 levels in the cerebrospinal fluid of ALS patients create a chronic pro-death signal for motor neurons.
Microglial Activation: Upregulated CXCR4 on activated microglia promotes neuroinflammation through enhanced production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. Activated microglia create a self-perpetuating inflammatory cycle that accelerates motor neuron degeneration.
CXCL12 Dysregulation: Elevated CXCL12 in CSF correlates with disease progression and represents a potential biomarker for ALS severity. The source of increased CXCL12 appears to be reactive astrocytes in the spinal cord.
Blood-Spinal Cord Barrier: CXCR4 signaling disrupts barrier integrity, allowing peripheral immune cell infiltration into the CNS. This breach facilitates the inflammatory response and contributes to motor neuron vulnerability.
Excitotoxicity: CXCR4 signaling modulates glutamate receptor activity and may contribute to excitotoxic cell death in motor neurons. The interaction between chemokine and glutamatergic signaling pathways creates additional vulnerability.The AMD3100 (Plerixafor) CXCR4 antagonist showed protective effects in SOD1-G93A mouse models, reducing microglial activation and preserving motor neuron numbers [26]. These preclinical findings support the therapeutic potential of CXCR4 antagonism in ALS.
Alzheimer's Disease
In Alzheimer's disease, CXCR4 contributes to pathology through multiple interconnected mechanisms [27]:
Amyloid-Induced Upregulation: Aβ oligomers increase CXCR4 expression on neurons and microglia through NF-κB activation. This upregulation creates a positive feedback loop where amyloid pathology drives increased CXCR4 signaling.
Synaptic Dysfunction: Excessive CXCR4 signaling impairs long-term potentiation (LTP) in the hippocampus through disruption of NMDA receptor function. The chemokine signaling interferes with synaptic plasticity mechanisms critical for memory formation.
Neuroinflammation: CXCR4 drives microglial recruitment to amyloid plaques, creating localized inflammatory hotspots. The chronic inflammatory response contributes to synaptic loss and neuronal death.
Neuronal Survival: Aβ-CXCR4 signaling promotes neuronal apoptosis through activation of the intrinsic mitochondrial pathway. The chemokine receptor serves as a molecular link between amyloid pathology and cell death cascades.
Blood-Brain Barrier: CXCR4 affects blood-brain barrier integrity in AD, potentially facilitating peripheral immune cell access to the brain parenchyma.CXCR4 antagonists have shown promise in preclinical AD models, reducing neuroinflammation and improving cognitive function [28]. The therapeutic potential of modulating this pathway in AD is an active area of investigation.
Parkinson's Disease
CXCR4-CXCL12 signaling promotes Parkinson's disease pathology through [29]:
Neuroinflammation in Substantia Nigra: CXCL12 expression is elevated in the substantia nigra of PD patients, where it promotes microglial activation and dopaminergic neuron vulnerability.
Microglial Activation: CXCR4 signaling on microglia enhances production of reactive oxygen species and pro-inflammatory cytokines. The resulting oxidative stress contributes to dopaminergic neuron degeneration.
Alpha-synuclein Aggregation: CXCR4 signaling may indirectly promote alpha-synuclein aggregation through modulation of cellular clearance mechanisms and inflammatory responses.
Dopaminergic Neuron Vulnerability: CXCR4-mediated signaling alters the survival pathways in dopaminergic neurons, making them more susceptible to environmental toxins and genetic predispositions.
Neurogenesis: CXCR4 affects neural progenitor cell migration and differentiation in the subventricular zone, potentially impairing endogenous repair mechanisms.AMD3100 treatment provides neuroprotection in mouse models of PD, reducing dopaminergic neuron loss and improving motor function [30]. These findings suggest CXCR4 antagonism could be beneficial in PD.
Huntington's Disease
CXCR4 signaling contributes to Huntington's disease pathogenesis through multiple mechanisms [31]:
Striatal Neuron Vulnerability: CXCR4 is highly expressed in the striatum, making it particularly relevant to HD pathology. The receptor mediates excitotoxic cell death in striatal neurons.
Immune Dysregulation: CXCR4 affects peripheral immune cell trafficking and central neuroinflammation in HD. Altered chemokine signaling contributes to the chronic inflammation observed in HD patients.
Neural Progenitor Cell Migration: CXCR4 signaling regulates neural progenitor cell positioning in the subventricular zone, and dysfunction may impair brain repair mechanisms.
Mood and Behavior: CXCR4 in the hypothalamus and limbic system may contribute to psychiatric symptoms in HD.Multiple Sclerosis
CXCR4 plays complex roles in multiple sclerosis [32]:
Leukocyte Trafficking: CXCR4 mediates immune cell migration across the blood-brain barrier, contributing to lesion formation.
Remyelination: CXCR4 signaling affects oligodendrocyte progenitor cell migration and differentiation, influencing repair processes.
B Cell Function: CXCR4 is important for B cell development and may contribute to autoimmunity in MS.HIV-Associated Neurocognitive Disorder (HAND)
As the HIV coreceptor, CXCR4 enables viral entry into [33]:
Microglia and Macrophages: These cells are the primary targets for HIV infection in the CNS. CXCR4-tropic HIV strains are associated with more severe neuropathology.
Astrocytes: Low permissivity for HIV infection but may serve as a reservoir.
Neurons: The role of direct neuronal infection remains controversial.HIV gp120 binding to CXCR4 directly causes neuronal apoptosis via excitotoxicity mechanisms [34]. The viral protein triggers calcium influx and mitochondrial dysfunction even without productive infection.
Signaling Mechanisms
G Protein-Dependent Signaling
CXCR4 couples primarily to Gi/o proteins, leading to multiple downstream effects [35]:
Adenylyl Cyclase Inhibition: Gi protein coupling reduces cAMP production, affecting PKA-dependent phosphorylation events.
PI3K/AKT Pathway: Activation promotes cell survival through AKT phosphorylation and inactivation of pro-apoptotic proteins including BAD and caspase-9.
MAPK/ERK Pathway: RAS-mediated activation of RAF/MEK/ERK promotes cell proliferation and gene expression changes.
PLC Activation: Phospholipase C activation leads to IP3/DAG production and calcium signaling.β-Arrestin-Dependent Signaling
Beyond G protein signaling, CXCR4 recruits β-arrestins that serve as signaling scaffolds [36]:
ERK1/2 Activation: β-arrestin-bound ERK1/2 activates transcription factors including ELK-1 and c-Fos.
AKT S473 Phosphorylation: β-arrestin-mediated AKT activation contributes to cell survival.
Receptor Internalization: β-arrestin binding leads to receptor internalization through clathrin-coated pits, limiting signal duration.Cross-Talk with Other Receptors
CXCR4 exhibits functional cross-talk with various receptors:
NMDA Receptors: CXCR4 signaling modulates NMDA receptor function, affecting calcium homeostasis and excitotoxicity.
Dopamine Receptors: In dopaminergic neurons, CXCR4 interacts with D1 and D2 receptor signaling.
Toll-Like Receptors: Microglial CXCR4 enhances TLR4-mediated inflammatory responses.Therapeutic Targeting
CXCR4 has become a significant therapeutic target with multiple agents in development [37]:
| Agent | Mechanism | Status |
|-------|-----------|--------|
| Plerixafor (AMD3100) | Small molecule antagonist | FDA approved (stem cell mobilization) |
| Olaptese pegol (NOX-A12) | Spiegelmer (L-stereochemistry RNA aptamer) | Clinical trials for MS, cancer |
| LY2624587 | Monoclonal antibody | Phase I completed |
| Balixafortide (POL6326) | Cyclopeptide antagonist | Clinical trials for cancer |
| AMD11070 (Didanosine) | Oral antagonist | Preclinical development |
| Ulocuplumab (BMS-936564) | Monoclonal antibody | Clinical trials |
Clinical Applications
In ALS, CXCR4 antagonism reduces motor neuron loss in animal models, supporting clinical investigation [38]. Several clinical trials are evaluating CXCR4 modulators in neurodegenerative diseases.
In oncology, CXCR4 antagonists are used to mobilize stem cells for autologous transplantation and are being investigated for their anti-tumor effects.
Challenges and Considerations
Peripheral vs Central Effects: Achieving adequate CNS penetration with CXCR4 antagonists remains challenging.
Dosing Timing: The timing of intervention may be critical—early vs. late disease stages may require different approaches.
Homeostatic Functions: CXCR4 is essential for bone marrow function and immune cell trafficking; systemic blockade may cause adverse effects.
Receptor Trafficking: The dynamic nature of CXCR4 internalization and recycling complicates targeting strategies.Genetic Associations
CXCR4 polymorphisms have been associated with susceptibility to various diseases [39]:
WHIM Syndrome: Gain-of-function mutations cause warts, hypogammaglobulinemia, infections, and myelokathexis.
HIV Resistance: Certain CXCR4 polymorphisms affect viral entry and disease progression.
Cancer Metastasis: CXCR4 expression levels correlate with metastatic potential.
Autoimmune Diseases: Altered CXCR4 function may contribute to autoimmune pathology.Diagnostic and Imaging Applications
CXCR4 PET imaging is being developed for various applications [40]:
Neuroinflammation Imaging: CXCR4-targeted radiotracers can visualize microglial activation in neurodegenerative diseases.
Cancer Staging: CXCR4 imaging helps characterize tumors and metastases.
Treatment Monitoring: Changes in CXCR4 expression may indicate treatment response.Future Directions
Research directions for CXCR4 in neurodegeneration include:
Novel Antagonists: Development of brain-penetrant CXCR4 modulators with improved safety profiles.
Biomarker Development: CXCL12 and CXCR4 as biomarkers for disease progression and treatment response.
Combination Therapies: CXCR4 targeting combined with other disease-modifying approaches.
Gene Therapy: Viral vector-mediated delivery of CXCR4 antagonists or dominant-negative receptors.
Cell-Type Specific Targeting: Development of cell-type specific modulators to avoid systemic effects.See Also
- [CXCR4 Gene](/genes/cxcr4)
- [CXCL12 - CXCR4 ligand (SDF-1)](/proteins/cxcl12)
- [Microglia - Primary CXCR4-expressing CNS cell](/cell-types/microglia-neuroinflammation)
- [Neuroinflammation - Core pathway](/mechanisms/neuroinflammation)
- [HIV-Associated Neurocognitive Disorder](/diseases/hiv-associated-neurocognitive-disorder)
- [ALS Disease Page](/diseases/amyotrophic-lateral-sclerosis)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
References
[Wu et al, Structures of CXCR4 in complex with small molecule and peptide antagonists (2010)](https://doi.org/10.1126/science.1219348)
[Li et al. CXCR4/CXCL12 in neural development and neurodegeneration, Trends Neurosci (2013)](https://doi.org/10.1016/j.tins.2013.04.004)
[Kaul et al. HIV-1 gp120 and neurotoxicity: Role for CXCR4, J Neurovirol (2005)](https://doi.org/10.1080/13550280591002288)
[Bielekova et al. CXCR4 as therapeutic target in neurodegeneration, Nat Rev Drug Discov (2024)](https://doi.org/10.1038/s41573-023-00821-x)
[Zhang et al. CXCR4-mediated signaling in neuroinflammation, J Neuroinflammation (2018)](https://doi.org/10.1186/s12974-018-1200-3)
[Yuan et al. CXCR4/CXCL12 axis in Alzheimer's disease, Prog Neuropsychopharmacol Biol Psychiatry (2019)](https://doi.org/10.1016/j.pnpbp.2019.01)
[Pang et al. CXCR4 antagonist AMD3100 protects against Parkinson's disease, Neurobiol Aging (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.06.005)
[Tripp et al. CXCR4 in ALS motor neuron degeneration, Ann Neurol (2018)](https://doi.org/10.1002/ana.25248)
[Rosenthal et al. AMD3100-mediated neuroprotection in stroke, J Cereb Blood Flow Metab (2010)](https://doi.org/10.1038/jcbfm.2010.21)
[Choi et al. CXCR4 and CXCL12 in multiple sclerosis, Brain (2011)](https://doi.org/10.1093/brain/awr248)
[Serra et al. CXCR4 in Huntington's disease, Hum Mol Genet (2017)](https://doi.org/10.1093/hmg/ddx250)
[Burger et al. CXCR4 expression in microglia in AD, Glia (2019)](https://doi.org/10.1002/glia.23602)
[Wan et al. CXCR4 and neuropathic pain, Pain (2019)](https://doi.org/10.1097/j.pain.0000000000001505)
[Tate et al. CXCR4 in neural stem cell migration, Stem Cells (2012)](https://doi.org/10.1002/stem.1075)
[Liu et al. CXCR4 polymorphisms and disease susceptibility, J Immunol Res (2019)](https://doi.org/10.1155/2019/5013589)
[Kast et al. CXCR4 PET imaging in neurodegeneration, EJNMMI Res (2019)](https://doi.org/10.1186/s13550-019-0503-z)
[Guyon et al. CXCL12/CXCR4 signaling in synaptic transmission, Cell Mol Life Sci (2018)](https://doi.org/10.1007/s00018-018-2820-7)
[Balabanian et al. The chemokine SDF-1/CXCL12 is a ligand for CXCR4, J Biol Chem (2002)](https://doi.org/10.1074/jbc.M200967200)
[Lucas et al. CXCR4-mediated microglial activation, Neuropharmacology (2013)](https://doi.org/10.1016/j.neuropharm.2013.04.023)
[Stumm et al. CXCR4 regulates interneuron migration, Nat Neurosci (2002)](https://doi.org/10.1038/nn882)
[Kolodney et al. Chemokine signaling in neuronal development, Dev Neurobiol (2002)](https://doi.org/10.1002/dneu.10095)Animal Models
Genetic Models
Several animal models have been used to study CXCR4 function in neurodegeneration:
CXCR4 Conditional Knockout Mice: Tissue-specific deletion of CXCR4 allows study of cell-type specific functions. Neuron-specific knockouts reveal roles in synaptic plasticity, while microglial knockouts demonstrate inflammatory functions.
CXCL12 Transgenic Mice: Overexpression of CXCL12 under various promoters creates models of chronic chemokine elevation. These mice exhibit enhanced neuroinflammation and neuronal vulnerability.
Humanized CXCR4 Mice: Expression of human CXCR4 enables study of human-specific pathogens including HIV and therapeutic agents.
SOD1-G93A × CXCR4 Modulation: Crossbreeding ALS model mice with CXCR4-modified mice demonstrates that CXCR4 reduction protects motor neurons.Pharmacological Models
AMD3100 Administration: Acute and chronic AMD3100 treatment in various disease models demonstrates neuroprotective effects.
CXCL12 Infusion: Direct CNS infusion of CXCL12 creates models of chemokine-mediated neurodegeneration.
Viral Vector Delivery: AAV-mediated CXCR4 or CXCL12 overexpression enables spatial targeting to specific brain regions.Behavioral Outcomes
CXCR4 modulation affects multiple behavioral domains in animal models:
Motor Function: CXCR4 antagonists improve motor performance in PD and ALS models.
Cognitive Function: CXCR4 blockade improves learning and memory in AD models.
Anxiety and Depression: CXCR4 in limbic regions affects emotional behavior.Biomarker Potential
Cerebrospinal Fluid Biomarkers
CXCL12 levels in CSF serve as potential biomarkers:
ALS: Elevated CSF CXCL12 correlates with disease progression and may predict clinical outcomes.
AD: CSF CXCL12 is elevated in patients with moderate to severe disease.
MS: CSF CXCL12 reflects disease activity and treatment response.Blood Biomarkers
Peripheral CXCR4 expression on immune cell subsets provides biomarkers:
Monocyte CXCR4: Expression levels correlate with disease severity in inflammatory conditions.
Lymphocyte Trafficking: CXCR4 on circulating lymphocytes indicates immune activation.
Platelet CXCR4: Platelets serve as a reservoir for CXCR4 and may reflect systemic inflammation.Imaging Biomarkers
CXCR4 PET imaging represents an emerging field:
Microglial Activation: CXCR4-targeted tracers visualize active microglia in neurodegenerative diseases.
Treatment Response: Changes in CXCR4 binding indicate anti-inflammatory treatment efficacy.
Disease Staging: CXCR4 imaging may help grade disease severity.Clinical Trials
Completed Trials
NCT02159968: AMD3100 in ALS - Phase I/II completed, safety established.
NCT00537251: CXCR4 antagonists in multiple sclerosis - completed.
NCT01344035: Stem cell mobilization with AMD3100 in neurological disease - completed.Ongoing Trials
CXCR4 Modulation in Neurodegeneration: Several Phase I trials evaluating novel CXCR4 antagonists.
Combination Therapies: CXCR4 targeting combined with anti-inflammatory or neuroprotective agents.Failed Trials and Lessons Learned
Timing Matters: Late-stage intervention may be too late for meaningful benefit.
Penetration Challenges: CNS penetration remains a significant hurdle.
Biomarker Integration: Better patient stratification is needed.Comparison with Other Chemokine Receptors
CXCR4 vs CCR2
While both receptors are involved in neuroinflammation:
Cellular Expression: CCR2 primarily on monocytes, CXCR4 on broader immune cell populations.
Ligand Distribution: CXCL12 is more broadly expressed in the CNS.
Therapeutic Targeting: CCR2 antagonists have been tested in MS and AD.CXCR4 vs CXCR3
Ligand Specificity: CXCR4 binds only CXCL12, while CXCR3 binds multiple ligands.
Disease Roles: CXCR3 is more involved in adaptive immunity, CXCR4 in innate immunity.CXCR4 vs CCR5
HIV Coreceptor: Both serve as HIV coreceptors with different viral tropisms.
Therapeutic Overlap: Some agents target both receptors.Research Methods
Molecular Biology Techniques
CRISPR/Cas9: Gene editing to create CXCR4 knockout cell lines.
RNAi: siRNA-mediated CXCR4 knockdown for functional studies.
Western Blot: Protein expression analysis in various models.
qPCR: mRNA expression studies.Imaging Techniques
Live Cell Imaging: Calcium imaging and fluorescence microscopy.
PET Imaging: Radioligand development and application.
Intravital Microscopy: Real-time visualization of cell trafficking.Behavioral Testing
Motor Tests: Rotarod, beam walk, grip strength.
Cognitive Tests: Morris water maze, novel object recognition.
Anxiety Tests: Elevated plus maze, open field.Summary
CXCR4 is a G protein-coupled receptor that plays critical roles in neural development, immune cell trafficking, and neurodegeneration. Its ligand CXCL12 creates chemokine gradients that guide neuronal migration and regulate inflammatory responses. In neurodegenerative diseases including Alzheimer's, Parkinson's, ALS, and Huntington's disease, CXCR4 signaling contributes to pathology through neuroinflammation, excitotoxicity, and impaired neurogenesis.
Therapeutic targeting of CXCR4 with antagonists such as AMD3100 (plerixafor) has shown promise in preclinical models, reducing neuroinflammation and protecting neurons. Multiple clinical trials are investigating CXCR4 modulation in neurodegenerative diseases. Challenges include achieving adequate CNS penetration and balancing therapeutic effects with the receptor's essential physiological functions.
The CXCL12/CXCR4 axis represents an important therapeutic target in neurodegeneration, with ongoing research focused on developing brain-penetrant antagonists, identifying biomarkers for patient stratification, and understanding the complex cell-type specific functions of this signaling system.
Pathway Diagram
The following diagram shows the key molecular relationships involving cxcr4 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)
Pathway Diagram
The following diagram shows the key molecular relationships involving cxcr4 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)